China Archives - TBC repository

Home
/
Projects

China

Facing up to reality? What to do if M72/AS01E doses are limited

The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a positive result, could be licensed by 2030. Modelling suggested a large potential impact from introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding the allocation of constrained doses on the potential global impact of M72/AS01E

Cost and Cost Effectiveness of Novel Tuberculosis Vaccines in Low-and Middle-income Countries: A Systematic Review of Modelling Studies

hypothetical, M72/AS01e

Ongoing

This review addressed the costs and cost-effectiveness of novel tuberculosis (TB) vaccines compared to the current standard of care (BCG) in various settings and for different age groups in LMICs

Part of Change 2.0

2024-2027

Hypothetical vaccines

Planned

Actionable market intelligence, including vaccine demand forecast/scenarios, generated to strategically guide manufacturers and partners in their planning for introduction in high burden countries. The objectives include: 1. Strategic assessment of appropriate market-shaping interventions, 2.Stakeholder and decision process mapping , 3.Demand dynamics understanding and realistic market forecast development, 4. Commercialization strategy support for lead candidate(s).

Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.

2019

Hypothetical vaccines

Completed

We modelled the potential impact of new tuberculosis vaccines in China targeting adolescents (15–19 years) or older adults (60–64 years) with varying vaccine characteristics to inform strategic vaccine development.

Potential impact of tuberculosis vaccines in China, South Africa, and India

2020

BCG revaccination, M72/AS01e

Completed

To inform vaccine development decision making, we modeled the impact of hypothetical tuberculosis vaccines in three high-burden countries.

The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug resistant tuberculosis in India and China

2021

Hypothetical vaccines

Completed

We investigated the epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic prevention of disease TB vaccines on RR/MDR-TB in China and India.

Mixed vaccination strategy for the control of tuberculosis: A case study in China

2017

Hypothetical vaccines

Completed

This study first presents a mathematical model of TB transmission considering BCG vaccination compartment to investigate the transmission dynamics nowadays

Affordability of adult tuberculosis vaccination in India and China: A dynamic transmission model-based analysis

2021

M72/AS01e

Completed

To estimate the total disability adjusted life years (DALYs) averted by the vaccination programme, we simulated a 50% efficacy vaccine providing 10-years of protection in post-infection populations between 2027 and 2050 in India and China using a dynamic transmission model of M. tuberculosis.

Is neglect of self-clearance biasing TB vaccine impact estimates?

2023

Hypothetical vaccines

Completed

exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India

Demand insights for uptake of TB vaccine

2022

Hypothetical vaccines

Completed

Summarize the major swing factors that would determine countries’ preference and effectively drive the uptake of a TB vaccine in terms of the date of introduction and the scale of catch-up campaign to reach the steady state